Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment

Pharmacological Research

Volumn 62, Issue 3, 2010, Pages 207-227

  Colalto, Cristiano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cytochrome P450; Drug absorption; Herb drug interactions; Herbal medicines; P glycoprotein; Pharmacogenetics; Risk assessment; Safety

Indexed keywords

ALPRAZOLAM; ANTICOAGULANT AGENT; BLACK TEA EXTRACT; BUSPIRONE; CAFFEINE; CAPSAICIN; CEFAZOLIN; CEFIXIME; CELIPROLOL; CHLORZOXAZONE; CLOZAPINE; CURCUMIN; DEBRISOQUINE; DEXTROMETHORPHAN; DICLOFENAC; DIOSMIN; ECHINACEA EXTRACT; EPIGALLOCATECHIN GALLATE; FOLIC ACID; GARLIC EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; LOSARTAN; METRONIDAZOLE; MIDAZOLAM; NIFEDIPINE; PLACEBO; SAQUINAVIR; TALINOLOL; UNINDEXED DRUG; PLANT MEDICINAL PRODUCT;

AREA UNDER THE CURVE; BLACK PEPPER; CLINICAL TRIAL; CURCUMA LONGA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECHINACEA; GARLIC; GINGER; GINKGO BILOBA; GINSENG; GLYCYRRHIZA GLABRA; GRAPEFRUIT JUICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERICUM PERFORATUM; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PEPPER; PLANT FIBER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SABAL; SENNA; SILYBUM MARIANUM; SINGLE DRUG DOSE; TEA; TIME TO MAXIMUM PLASMA CONCENTRATION; VALERIANA OFFICINALIS; VASCULAR DISEASE; ANIMAL; HERB DRUG INTERACTION; HERBAL MEDICINE; PHARMACOKINETICS;

ANIMALS; HERB-DRUG INTERACTIONS; HERBAL MEDICINE; HUMANS; PHARMACOKINETICS; PLANT PREPARATIONS;

EID: 77954144994     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.04.001     Document Type: Review

References (273)

1. Goldman P., Peppercorn M.A., Goldin B.R. Metabolism of drugs by microorganisms in the intestine. Am J Clin Nutr 1974, 27:1348-1355.
2. Xie H.G., Kim B., Wood A.J.J., Stein C.M. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001, 41:815-850.
3. Juurlink D.N., Mamdani M., Kopp A., Laupacis A., Redelmeier D.A. Drug-drug interactions among hospitalized for drug toxicity. JAMA 2003, 289(13):1652-1658.
4. Gandhi M., Aweeka F., Greenblatt R.M., Blaschke T.F. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004, 44:499-523.
5. Streubel A., Siepmann J., Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol 2006, 6:501-508.
6. Terada T., Inui K. Gene expression and regulation of drug transporter in the intestine and kidney. Biochem Pharmacol 2007, 73:440-449.
7. Franconi F., Brunelleschi S., Steardo L., Cuomo V. Gender differences in drug responses. Pharmacol Res 2007, 55(2):81-95.
8. Baraldo M. The influence of circadian rhytms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 2008, 4(2):175-192.
9. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs. A systematic review. Drugs 2001, 61(15):2163-2175.
10. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279:1200-1205.
11. Einsenberg D., Davis R., Ettner S., Appel S., Wilkey S., Van Rompay M., et al. Trends in alternative medicines use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998, 280:1569-1575.
12. Richardson M.A., Sanders T., Palmer J.L., Greisinger A., Singletary S.E. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncoloy. J Clin Oncol 2000, 18:2505-2514.
13. Ang-Lee M.K., Moss J., Yuan C.-S. Herbal medicines and perioperative care. JAMA 2001, 286(2):208-216.
14. Kaufman D.W., Kelly J.P., Rosemberg L., Anderson T.E., Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the United States. JAMA 2002, 287:337-344.
15. Wold R.S., Lopez S.T., Yau L., Butler L.M., Pareo-Tubbeh S.L., Waters D.L., et al. Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J Am Diet Assoc 2005, 105:54-63.
16. Shanrokh L.E., Lukaszur J.M., Prawitz A.D. Elderly herbal supplement users less satisfied with medical care than nonusers. J Am Diet Assoc 2005, 105:1138-1140.
17. Fugh-Berman A. Herb-drug interactions. Lancet 2000, 355:134-138.
18. Vaes L.P., Chyka P.A. Interactions of warfarin with garlic, ginger ginkgo or ginseng: nature of the evidence. Ann Pharmacother 2000, 34:1478-1482.
19. Brazier N.C., Mitchell A.H., Levine M.D. Understanding drug-herb interaction. Pharmacoepidemiol Drug Saf 2003, 12:427-430.
20. Sparreboom A., Cox M.C., Acharya M.R., Figg W.D. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004, 22(12):2489-2503.
21. De Smet P.A.G.M. Clinical risk management of herb-drug interactions. Br J Pharmacol 2006, 63(3):258-267.
22. Chavez M.L., Jordan M.A., Chavez P.I. Evidence-based drug-herbal interactions. Life Sci 2006, 78:2146-2157.
23. Butterweck V., Derendorf H. Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clin Pharmacokinet 2008, 47(6):383-397.
24. Butterweck V., Derendorf H., Gaus W., Nahrstedt A., Schulz V., Unger M. Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate?. Planta Med 2004, 70(9):784-791.
25. Coppens P., Delmulle L., Gulati O., Richardson D., Ruthsatz M., Sievers H., et al. Use of botanical in food supplements. Ann Nutr Metab 2006, 50:538-554.
26. Kroes R., Walker R. Safety issues of botanicals and botanical preparations in functional foods. Toxicology 2004, 194:213-220.
27. Schilter B., Andersson C., Anton R., Constable A., Kleiner J., O'Brien J., et al. Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements. Food Chem Toxicol 2003, 41:1625-1649.
28. EMEA Commitee on Herbal Medicinal Products (HMPC). Guideline on the assessment of clinical safety and efficacy in the preparation of community herbal monographs for well-estabilished and of community herbal monographs/entries to the community list for traditional harbal medicinal products/substances/preparations. 2006. Doc. Ref. EMEA/HMPC/104613/2005 [cited 2008 Dec 1]. Avaible from: http://www.emea.europa.eu/pdfs/human/hmpc/10461305en.pdf.
29. U.S. Department of Health and Human Services, Office of Inspector General. Adverse event reporting for dietary supplements: an inadequate safety valve 2001 [cited 2008 Dec 1]. Avaible from: http://oig.hhs.gov/oei/reports/oei-01-00-00180.pdf.
30. Rietjens I.M.C.M., Slob W., Galli C., Silano V. Risk assessment of botanical preparations intended for use in food and food supplements: emerging issues. Toxicol Lett 2008, 180(2):131-136.
31. Ajayi F.O., Sun H., Perry J. Adverse drug reactions: a review of relevant factors. J Clin Pharmacol 2000, 40:1093-1101.
32. Ernst E. Herbal medicines: balancing benefits and risks. Novartis Found Symp 2007, 282:154-172. 212-218.
33. De Smet P.A.G.M. Herbal remedies. N Engl J Med 2002, 347(25):2046-2056.
34. Gilroy C.M., Steiner J.F., Byers T., Shapiro H., Georgian W. Echinacea and truth in labeling. Arch Intern Med 2003, 163:699-704.
35. Krochmal R., Hardy M., Bowerman S., Lu Q.-Y., Wang H.-J., Elashoff R.M., et al. Phytochemical assays of commercial botanical dietary supplements. Evid Based Complement Altern Med 2004, 1:305-313.
36. Restani P., Persico A., Ballabio C., Moro E., Fuggetta D., Colombo M.L. Analysis of food supplements containing iodine: a survey of Italian market. Clin Toxicol 2008, 46(4):282-286.
37. Garrard J., Harms S., Eberly L.E., Matiak A. Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med 2003, 163:2290-2295.
38. Poon W.T., Nq S.W., Lai C.K., Chan Y.W., Mak W.L. Factitious thyrotoxicosis and herbal dietary supplement for weight reduction. Clin Toxicol (Phila) 2008, 46(4):290-292.
39. Gurley B.J., Swain A., Hubbard M.A., Williams D.K., Barone G., Hartsfield F., et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effect of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008, 52(7):755-763.
40. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Carrier J., et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004, 76:428-440.
41. Markowitz J.S., DeVane C.L., Chavin K.D., Taylor R.M., Ruan Y., Donovan J.L. Effect of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003, 74:170-177.
42. Barnes J., Mills S.Y., Abbot N.C., Willoughby M., Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998, 45:496-500.
43. Cuzzolin L., Zaffani S., Benoni G. Safety implications regarding use of phytomedicines. Eur J Clin Pharmacol 2006, 62:37-42.
44. Bacchini M., Cuzzolin L., Camerlengo T., Velo G. Phytotherapic compounds: the consumer-pharmacist relationship. Drug Saf 2008, 31(5):424-427.
45. Fugh-Berman A., Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001, 52:587-595.
46. Lopez-Gonzales E., Herdeiro M.T., Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009, 32(1):19-31.
47. De Smet P.A.G.M. Herbal medicine in Europe - relaxing regulatory standards. N Engl J Med 2005, 352(12):1176-1178.
48. Palmer M.E., Haller C., McKinney P.E., Klein-Schwartz W., Tschirgi A., Smolinske S.C., et al. Adverse events associated with dietary supplements: an observational study. Lancet 2003, 361:101-106.
49. van Roon E.N., Flikweert S., le Comte M., Langendijk P.N., Kwee-Zuiderwijk W.J., Smits P., et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 2005, 28:1131-1139.
50. Steinijans V.W., Hartmann M., Huber R., Radtke H.W. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991, 29(8):323-328.
51. EMEA Commitee for Propietary Medicinal Products (CPMP). Note for guidance on the investigation of drug interactions. 1997 Doc. Ref. CPMP/EWP/560/95 [cited 2008 Dec 1]. Avaible from: http://www.emea.europa.eu/pdfs/human/ewp/056095en.pdf.
52. Fuhr U. What is the true risk of a pharmacokinetic drug-drug interaction. Eur J Clin Pharmacol 2007, 63:897-899.
53. Fuhr U. Improvement in the handling of drug-drug interaction. Eur J Clin Pharmacol 2008, 64:167-171.
54. Huang S.-M., Strong J.M., Zhang L., Reynolds K.S., Nallani S., Temple R., et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008, 48(6):662-670.
55. FDA Guidance for industry: in vivo drug metabolism/drug interaction studies - study design, data analysis, and raccomandations for dosing and labeling 1999 [cited 2008 Dec 1]. Avaible from: http://www.fda.gov/CbER/gdlns/metabol.htm.
56. Ogata H., Aoyagi N., Kaniwa N., Ejima A., Sekine N., Kitamura M., et al. Gastric acidity dependent biovailability of cinnarizine from two commercial capsules in healthy volunteers. Int J Pharm 1986, 29:113-120.
57. Satoh C., Sakai T., Kashiwagi H., Hongo K., Aizawa O., Watanabe H., et al. Influence of cisapride on the pharmacokinetics and antihypertensive effect of sustained-release nifedipine. Intern Med 1996, 35(12):941-945.
58. Kim H.-R., Park S.-W., Cho H.-J., Chae K.-A., Sung J.-M., Kim J.-S., et al. Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacol Res 2007, 56:224-236.
59. Tsuji A., Tamai I., Nakanishi M., Terasaki T., Hamano S. Intestinal brush-border transport of the oral cephalosporin antibiotic, cefdinir, mediated by dipeptide and monocarboxylic acid transport system in rabbits. J Pharm Pharmacol 1993, 45:996-998.
60. De Vrueh R.L.A., Smith P.L., Lee C.-P. Transport of L-valine aciclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. J Pharmacol Exp Ther 1998, 286:1166-1170.
61. Terada T., Sawada K., Irie M., Saito H., Hashimoto Y., Inui K. Structural requirements for determining the substrate affinity of peptide transporter Pept1 and Pept2. Pflugers Arch 2000, 440:679-684.
62. Steffansen B., Nielsen C.U., Brodin B., Eriksson A.H., Andersen R., Frokjaer S. Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci 2004, 21:3-16.
63. Kobayashi D., Nozawa T., Imai K., Nezu J.-I., Tsuji A., Tamai I. Involvement of human organic anion transporting polypeptide OATPB (SLC21A9) in ph dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003, 306:703-708.
64. Hennessy M., Spiers J.P. A primer on the mechanics of P-glycoprotein in the multidrug transporter. Pharmacol Res 2007, 55:1-15.
65. Christians U., Schmitz V., Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 2005, 1(4):641-654.
66. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75(1):13-33.
67. Yang J., Jamei M., Yeo K.R., Tucker G.T., Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007, 8(7):676-684.
68. Genser D. Food and drug interaction: consequence for the nutrition/health status. Ann Nutr Metab 2008, 52(Suppl 1):S29-S32.
69. Undevia S.D., Gomez-Abuin G., Ratain M.J. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005, 5:447-458.
70. Kolars J.C., Awni W.M., Merion R.M., Watkins P.B. First-Pass metabolism of cyclosporin by the gut. Lancet 1991, 338:1488-1490.
71. López-Rodríguez R., Novalbos J., Gallego-Sandín S., Román-Martínez M., Torrado J., Gisbert J.P., et al. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol Res 2008, 58:77-84.
72. Galetin A., Houston J.B. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 2006, 318(3):1220-1229.
73. Lown K.S., Ghosh M., Watkins P.B. Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metab Dispos 1998, 26(2):185-187.
74. Doherty M.M., Charman W.N. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?. Clin Pharmacokinet 2002, 41(4):235-253.
75. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352:2211-2221.
76. Blumenthal M. Herbs continue slide in mainstream market: sales down 14 percent. HerbalGram [internet] 2003 [cited 2008 Dec 1];58:71. Avaible from: http://cms.herbalgram.org/herbalgram/issue58/article2501.html.
77. Borrelli F., Capasso R., Izzo A.A. Garlic (Allium sativum L.): adverse effects and drug interactions in humans. Mol Nutr Food Res 2007, 51:1386-1397.
78. Macan H., Uykimpang R., Alconcel M., Takasu J., Razon R., Amagase H., et al. Significance of Garlic and its constituents in cancer and cardiovascular disease: aged garlic extract may be safe for patients on warfarin therapy. J Nutr 2006, 136(Suppl 3):S793-S795.
79. Foster B.C., Foster M.S., Vandenhoek S., Krantis A., Budzinski J.W., Arnason J.T., et al. An in vitro evaluation of human cytochrome P450 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001, 4(2):176-184.
80. Greenblatt D.J., Leigh-Pemberton R.A., von Moltke L.L. In vitro interactions of water-soluble garlic components with humans cytochromes p450. J Nutr 2006, 136(Suppl 3):S806-S809.
81. Munday R., Munday C.M. Low doses of diallyl disulfide, a compound derived from garlic, increase tissue activities of quinone reductase and glutathione transferase in the gastrointestinal tract of the rat. Nutr Cancer 1999, 34(1):42-48.
82. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry B.W., Cui Y., et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002, 72:276-287.
83. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Cui Y., et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005, 22:525-539.
84. Gallicano K., Foster B., Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003, 55:199-202.
85. Piscitelli S.C., Burstein A.H., Welden N., Gallicano K.D., Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002, 34:234-238.
86. Garbisa S., Biggin S., Cavallarin N., Sartor L., Benelli R., Albini A. Tumor invasion: molecular shears blunted by green tea. Nat Med 1999, 5(11):1216.
87. Dell'Aica I., Donà M., Tonello F., Piris A., Mock M., Montecucco C., et al. Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep 2004, 5(4):418-422.
88. Antonello M., Montemurro D., Bolognesi M., Di Pascoli M., Piva A., Greco F., et al. Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. Am J Hypertens 2007, 20(12):1321-1328.
89. Devika P.T., Stanely Mainzen Prince P. (-)Epigallocatechin-gallate (EGCG) prevents mitochondrial damage in isoproterenol-induced cardiac toxicity in albino Wistar rats: a transmission electron microscopic and in vitro study. Pharmacol Res 2008, 57:351-357.
90. Richard D., Kefi K., Barbe U., Poli A., Bausero P., Visioli F. Weight and plasma lipid control by decaffeinated green tea. Pharmacol Res 2009, 59:351-354.
91. Papparella I., Ceolotto G., Montemurro D., Antonello M., Garbisa S., Rossi G., et al. Green tea attenuates angiotensin II-induced cardiac hypertrophy in rats by modulating reactive oxygen species production and the Src/epidermal growth factor receptor/Akt signaling pathway. J Nutr 2008, 138(9):1596-1601.
92. Babu P.V.A., Sabitha K.E., Srinivasan P., Shyamaladevi C.S. Green tea attenuates diabetes induced Maillard-type fluorescence and collagen cross-linking in the heart of streptozotocin diabetic rats. Pharmacol Res 2007, 55:433-440.
93. Jodoin J., Demeule M., Béliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 2002, 1542:149-159.
94. Fuchikami H., Satoh H., Tsujimoto M., Ohdo S., Ohtani H., Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2006, 34:577-582.
95. Netsch M.I., Gutmann H., Schmidlin C.B., Avdogan C., Drewe J. Induction of CYP1A by green tea extract in human cell lines. Planta Med 2006, 72(6):514-520.
96. Nishikawa M., Ariyoshi N., Kotani A., Ishii I., Nakamura H., Nakasa H., et al. Effects of continuous ingestion of Green Tea or Grape Seed extracts on the pharmacokinetics of midazolam. Drug Metab Pharmacokinet 2004, 19(4):280-289.
97. Jang E.H., Choi J.Y., Park C.S., Lee S.K., Kim C.E., Park H.J., et al. Effects of green tea extract administration on the pharmacokinetics of clozapine in rats. J Pharm Pharmacol 2005, 57(3):311-316.
98. Donovan J.L., Chavin K.D., DeVane C.L., Taylor R.M., Wang J.-S., Ruan Y., et al. Short Communication: Green Tea (Camellia sinensis) extract does not alter cytochrome P450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 2004, 32(9):906-908.
99. Sherry Chow H.-H., Hakim I.A., Vining D.R., Crowell J.A., Cordova C.A., Chew W.M., et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 2006, 15(12):2473-2476.
100. Alemdaroglu N.C., Wolffram S., Boissel J.P., Closs E., Spahn-Langguth H., Langguth P. Inhibition of folic acid uptake by catechins and tea extracts in Caco-2 cells. Planta Med 2007, 73:27-32.
101. Alemdaroglu N.C., Dietz U., Wolffram S., Spahn-Langguth H., Langguth P. Influence of green tea and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid biovailability. Biopharm Drug Disp 2008, 29(6):335-348.
102. Han Y., Tan T.C.T., Lim L.-Y. Effects of capsaicin on P-gp function and expression in Caco-2 cells. Biochem Pharmacol 2006, 71:1727-1734.
103. Komori Y., Aiba Y., Nakai C., Sugiyama R., Kawasaki H., Kurosaki Y. Capsaicin-induced increase of intestinal cefazolin absorption in rats. Drug Metab Pharmacokinet 2007, 22(6):445-449.
104. Uduphille M. The effect of capsaicin on the small intestine absorption of glucose and alanine in the rat. Indian J Physiol Pharmacol 1993, 37:59-62.
105. Cruz L., Castañeda-Hernandez G., Navarrete A. Ingestion of chilli pepper (Capsicum annuum) reduces salicylate biovailability after oral aspirin administration in the rat. Can J Physiol Pharmacol 1999, 77:441-446.
106. Hatakeyama Y., Matsuo M., Tomoi M., Ohtsuka M., Shimomura K. Luminal diluition caused by certain mild irritants and capsaicin contributes to their gastric mucosal protection. Am J Physiol Gastrointest Liver Physiol 1995, 268(2 Pt 1):200-206.
107. Takeuchi K., Niidia H., Matsumoto J., Ueshima K., Okabe S. Gastric motility in capsaicin-induced cytoprotection in the rat stomach. Jpn J Pharmacol 1991, 55(1):147-155.
108. Limlomwongse L., Chaitauchawong C., Tongyai S. Effect of capsaicin on gastric acid secretion and mucosal blood flow in the rat. J Nutr 1979, 109(5):773-777.
109. Debreceni A., Abdel-Salam O.M.E., Fingler M., Juricskay I., Szolcsányi J., Mòzsik G. Capsaicin increases gastric emptying rate in healthy human subjects measured by C-labeled octanoic acid breath test. J Physiol Paris 1999, 93:455-460.
110. Tuntipopipat S., Judprasong K., Zeder C., Wasantwisut E., Winichagoon P., Charoenkiatkul S., et al. Chili, but not turmeric, inhibits iron absortpion in young women from a iron-fortified composite meal. J Nutr 2006, 136:2970-2974.
111. Izzo A.I., Sautebin L., Rombolà L., Capasso F. The role of constitutive nitric oxide synthase in senna- and cascara-induced diarrhoea in the rat. Eur J Pharmacol 1997, 323:93-97.
112. Laitinen L., Takala E., Vuorela H., Vuorela P., Kaukonen A.M., Marvola M. Anthranoid laxative influence the absorption of poorly permeable drugs in human intestinal cell culture model (Caco-2). Eur J Pharm Biopharm 2007, 66:135-145.
113. Yao L.H., Jiang Y.M., Shi J., Tomàs-Barberàn F.A., Datta N., Singanusong N., et al. Flavonoids in food and their health benefits. Plant Foods Hum Nutr 2004, 59(3):113-122.
114. Mojzis J., Varinska L., Mojzisova G., Kostova I., Mirossay L. Antiangiogenic effects of flavonoids and chalcones. Pharmacol Res 2008, 57:259-265.
115. Hong S.S., Seo K., Lim S.-C., Han H.-K. Interaction characteristics of flavonoids with human organic anion transporter 1 (hOAT1) and 3 (hOAT3). Pharmacol Res 2007, 56:468-473.
116. Schmiedlin-Ren P., Edwards D.J., Fitzsimmons M.E., He K., Lown K.S., Woster P.M., et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997, 25(11):1228-1233.
117. Spahn-Langguth H., Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Europ J Pharm Sci 2001, 12:361-367.
118. Dahan A., Altman H. Food-drug interaction: grapefruit juice augments drug biovailability mechanism, extent and relevance. Eur J Clin Nutr 2004, 58:1-9.
119. Bailey D.G., Dresser G.K., Leake B.F., Kim R.B. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007, 81(4):495-502.
120. Greenblatt D.J., Patki K.C., von Moltke L.L., Shader R.I. Drug interaction with grapefruit juice: an update. J Clin Psychopharmacol 2001, 21:357-359.
121. Lown K.S., Bailey D.G., Fontana R.J., Janardan S.K., Adair C.H., Fortlage L.A., et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997, 99(10):2545-2553.
122. Bailey D.G., Arnold J.M., Strong H.A., Munoz C., Spence J.D. Effect of grapefruit juice and narigin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993, 54:589-594.
123. Bailey D.G., Arnold M.O., Bend J.R., Tran L.T., Spense J.D. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995, 40:135-140.
124. Edgar B., Bailey D., Bergstrand R., Johnason G., Regårdh C.G. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine and its potential clinical relevance. Eur J Clin Pharmacol 1992, 42:313-317.
125. Gleaser H., Bailey D.G., Dresser G.K., Gregor J.C., Schwarz U.I., McGrath J.S., et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007, 81(3):362-370.
126. Rashid T.J., Martin U., Clarke H., Waller D.G., Renwick A.G., George C.F. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995, 40:51-58.
127. Farkas D., Greenblatt D.J. Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 2008, 4(4):381-393.
128. Yoo H.H., Lee M., Chung H.J., Lee S.Y., Kim D.H. Effects of Diosmin, a flavonoid glycoside in citrus fruits, on P-Glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J Agric Food Chem 2007, 55:7620-7625.
129. Wenzel U., Kuntz S., Daniel H. Flavonoids with epidermal growth factor-receptor tyrosine kinase inhibitory activity stimulate PEPT1-mediated cefixime uptake into human intestinal epithelial cells. J Pharmacol Exp Ther 2001, 299:351-357.
130. Rajnarayana K., Reddy M.S., Krishma D.R. Diosmin pretreatment affects biovailability of metronidazole. Eur J Clin Pharmacol 2003, 58:803-807.
131. Rajnarayana K., Venkatesham A., Krishna D.R. Biovailability of diclofenac sodium after pretreatment with diosmin in healthy volunteers. Drug Metabol Drug Interact 2007, 22:165-174.
132. Jagetia G.C., Aggarwal B.B. " Spicing Up" of the immune system by curcumin. J Clin Immunol 2007, 27(1):19-35.
133. Meheshwari R.K., Singh A.K., Gaddipati J., Srimal R.C. Multiple biological activities of curcumin: a short review. Life Sci 2006, 78:2081-2087.
134. Yodkeeree S., Chaiwangyen W., Garbisa S., Limtrakul P. Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPa. J Nutr Biochem 2009, 20(2):87-95.
135. Hou X.L., Takahashi K., Tanaka K., Tougou K., Qiu F., Komatsu K., et al. Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. Int J Pharm 2008, 358:224-229.
136. 3 treated Caco-2 cells. Int J Pharm 2007, 337:169-177.
137. Naganuma M., Saruwatari A., Okamura S., Tamura H. Turmeric and curcumin modulate the conjugation of 1-naphtol in Caco-2 cells. Biol Pharm Bull 2006, 29:1476-1479.
138. Zhang W., Chin Tan T.M., Lim L.-Y. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 2006, 35(1):110-115.
139. Basu N.K., Kole L., Basu M., McDonagh A.F., Owens I.S. Targeted inhibition of glucuronidation markedly improves drug efficacy in mice-a model. Biochem Biophys Res Commun 2007, 360:7-13.
140. Juan H., Terhaag B., Cong Z., Bi-Kui Z., Rong-Hua Z., Feng W., et al. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol 2007, 63:663-668.
141. Raduner S., Majewska A., Chen J.-Z., Xie X.-Q., Hamon J., Faller B., et al. Alkylamides from Echinacea are a new class of cannabinomimetics Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem 2006, 281(20):14192-14206.
142. Woelkart K., Bauer R. The role of alkamides as an active principle of echinacea. Planta Med 2007, 73(7):615-623.
143. Shah S.A., Sander S., White C.M., Rinaldi M., Coleman C.J. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. Lancet Infect Dis 2007, 7:473-480.
144. Hellum B.H., Nilsen O.G. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008, 102:466-475.
145. Modarai M., Gertsch J., Suter A., Heinrich M., Kortenkamp A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamides content. J Pharm Pharmacol 2007, 59:567-573.
146. Gurley B.J., Swain A., Williams D.K., Barone G., Battu S.K. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008, 52(7):772-779.
147. Gorski J.C., Huang S.M., Pinto A., Hamman M.A., Hilligoss J.K., Zaheer N.A., et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004, 75(1):89-100.
148. Dubey A.K., Shankar P.R., Upadhvava D., Deshpande V.Y. Ginkgo biloba - an appraisal. Kathmandu Univ Med J 2004, 2(3):225-229.
149. ®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol Res 2009, 60:68-73.
150. Abdel-Kader R., Hauptmann S., Keil U., Scherping I., Leuner K., Eckert A., et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 2007, 56:493-502.
151. Zou L., Harkey M.R., Henderson G.L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002, 71:1579-1589.
152. Tang J., Sun J., Zhang Y., Li L., Cui F., He Z. Herb-drug interaction: effect of Ginkgo biloba extract on the pharmacokinetics of theophylline in rats. Food Chem Toxicol 2007, 45:2441-2445.
153. Yin O.Q.P., Tomlinson B., Waye M.M.Y., Chow A.H.L., Chow M.S.S. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004, 14:841-850.
154. Lei H.-P., Wang G., Wang L.-S., Ou-yang D.-S., Chen H., Li Q., et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in chinese volunteers identified as CYP2C19 poor and estensive metabolizers. Ann Pharmacother 2009, 43:726-731.
155. Markowitz J.S., Donovan J.L., DeVane L., Sipkes L., Chavin K.D. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 2003, 23(6):576-581.
156. Lu W.J., Huang J.D., Lai M.L. The effects of ergoloid mesylates and Ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol 2006, 46(6):628-634.
157. Yoshioka M., Ohnishi N., Koishi T., Obata Y., Nakagawa M., Matsumoto T., et al. Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004, 27(12):2006-2009.
158. Rowin J., Lewis S.L. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996, 46(6):1775-1776.
159. Matthews M.K. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998, 50:1933-1934.
160. Kupiec T., Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol 2005, 29:755-758.
161. Gaudineau C., Beckerman R., Welbourn S., Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun 2004, 318:1072-1078.
162. Greenblatt D.J., von Moltke L.L., Luo Y., Perloff E.S., Horan K.A., Bruce A., et al. Ginkgo biloba does not alter clearence of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 2006, 46(2):214-221.
163. Jiang X., Williams K.M., Liauw W.S., Ammit A.J., Roufogalis B.D., Duke C.C., et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005, 59(4):425-432.
164. Mauro V.F., Mauro L.S., Kleshinski J.F., Khunder S.A., Wang Y., Erhardt P.W. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 2003, 10(4):247-251.
165. Fan L., Mao X.-Q., Tao G.-Y., Wang G., Jiang F., Chen Y., et al. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica 2009, 39(3):249-254.
166. Fan L., Tao G.-Y., Wang G., Chen Y., Zhang W., He Y.-J., et al. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy chinese volunteers. Ann Pharmacother 2009, 43:944-949.
167. Robertson S.M., Davey R.T., Voell J., Formentini E., Alfaro R.M., Penzak S.R. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008, 24(2):591-599.
168. Penzak S.R., Busse K.H., Robertson S.M., Formentini E., Alfaro R.M., Davey R.T. Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharmacol 2008, 48:671-680.
169. Bone K.M. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoaugulant drugs: what is the evidence?. Mol Nutr Food Res 2008, 52:764-771.
170. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., et al. Association between CYP2C9 genetic variants and anticoaugulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
171. The international warfarin pharmacogenetics consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360(8):753-64.
172. Kim M.-J., Huang S.-M., Meyer U.A., Rahman A., Lesko L.J. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol 2009, 49:138-146.
173. Armanini D., Bonanni G., Palermo M. Reduction of serum testosterone in men by licorice. N Engl J Med 1999, 341:1158.
174. Menegazzi M., Di Paola R., Mazzon E., Genovese T., Crisafulli C., Dal Bosco M., et al. Glycyrrhizin attenuates the development of carrageenan-induced lung injury in mice. Pharmacol Res 2008, 58:22-31.
175. Asl M.N., Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytotherapy Res 2008, 22:709-724.
176. Armanini D., Karbowiak I., Funder J.W. Affinity of liquorice derivatives for mineralcorticoid and glucocorticoid receptors. Clin Endocrinol (Oxf) 1983, 19(5):609-612.
177. Aly A.M., Al-Alousi L., Salem H.A. Licorice. A possible anti-inflammatory and anti-ulcer drug. AAPS PharmSciTech 2005, 6:74-82.
178. Nabekura T., Yamaki T., Ueno K., Kitagawa S. Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol 2008, 62(5):867-873.
179. Cantelli-Forti G., Maffei F., Hrelia P., Bugamelli F., Bernardi M., D'Intino P., et al. Interaction of licorice on glycyrrhizin pharmacokinetics. Environ Health Perspect 1994, 102(Suppl 9):S65-S68.
180. Dell'Aica I., Caniato R., Biggin S., Garbisa S. Matrix proteases, green tea, and St John's wort: biomedical research catches up with folk medicine. Clin Chim Acta 2007, 381:69-77.
181. Behnke K., Jensen G.S., Graubaum H.J., Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of wild to moderate depression. Adv Ther 2002, 19(1):43-52.
182. Chatterjee S.S., Bhattacharya S.K., Wonnemann M., Singer A., Müller W.E. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci 1998, 63(6):499-510.
183. Donà M., Dell'Aica I., Pezzato E., Sartor L., Calabrese F., Della Barbera M., et al. Hyperforin inhibits cancer invasion and metastasis. Cancer Res 2004, 64:6225-6232.
184. Dell'Aica I., Niero R., Piazza F., Cabrelle A., Sartor L., Colalto C., et al. Hyperforin blocks neutrophil activation of matrix metalloproteinase-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis. J Pharmacol Exp Ther 2007, 321:492-500.
185. Lorusso G., Vannini N., Sogno I., Generoso L., Garbisa S., Noonan D.M., et al. Mechanisms of hyperforin as an anti-angiogenic angioprevention agent. Eur J Cancer 2009, 45(8):1474-1484.
186. Gutmann H., Poller B., Büter K.B., Pfunder A., Schaffner W., Drewe J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?. Planta Med 2006, 72(8):685-690.
187. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Wilson T.M., et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000, 97(13):7500-7502.
188. Hennessy M., Kelleher D., Spiers J.P., Barry M., Kavanagh P., Back D., et al. St John's wort increases expression of P-glycoprotein: Implications for drug interactions. Br J Clin Pharmacol 2002, 53:75-82.
189. Madabushi R., Frank B., Drewelow B., Derendorf H., Butterweck V. Hyperforin in St. John's wort drug interactions. Eur J Pharmacol 2006, 62:225-233.
190. Mills E., Montori V.M., Wu P.W., Gallicano K., Clarke M., Guyatt G. Interaction of St John's wort with conventional drugs: systemic review of clinical trials. BMJ 2004, 329:27-30.
191. Schwarz U.I., Hanso H., Oertel R., Miehlke S., Kuhlisch E., Gleaser H., et al. Induction of intestinal P-glycoprotein by St John's wort reduces the oral biovailability of talinolol. Clin Pharmacol Ther 2007, 81(5):669-678.
192. Dürr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., et al. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000, 68:598-604.
193. Mai I., Bauer S., Perloff E.S., Johne A., Uehleke B., Frank B., et al. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004, 76(4):330-340.
194. FDA public health advisory. Risk of drug interaction with St John's wort and indinavir and other drugs. 2000 Feb 10 [cited 2008 Dec 1]. Avaible from: http://www.fda.gov/Cder/drug/advisory/stjwort.htm.
195. Nah S.-Y., Kim D.-H., Rhim H. Ginsenosides: are any of them candidates for drugs acting on the central nervous system?. CNS Drug Rev 2007, 13(4):381-404.
196. Hiai S., Yokoyama H., Oura H., Yano S. Stimulation of pituitary-adrenocortical system by ginseng saponin. Endocrinol Jpn 1979, 26:661-665.
197. Jin J., Shahi S., Kang H.K., van Veen H.W., Fan T.-P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 2006, 345:1308-1314.
198. Kim S.-W., Kwon H.Y., Chi D.-W., Shim J.-H., Park J.-D., Lee Y.-H., et al. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol 2003, 65:75-82.
199. Merino G., Molina A.J., Garcia J.L., Puldido M.M., Prieto J.G., Alvarez A.I. Ginseng increases intestinal elimination of albendazole sulfoxide in the rat. Comp Biochem Physiol C 2003, 136:9-15.
200. Jiang X., Williams K.M., Liauw W.S., Ammit A.J., Roufogalis B.D., Duke C.C., et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004, 57(5):592-599.
201. Janetzky K., Morreale A.P. Probable interactions between warfarin and ginseng. Am J Health Syst Pharm 1997, 54:692-693.
202. Yuan C.-S., Wel G., Dey L., Karrison T., Nahlik L., Maleckar S., et al. Brief communication: American ginseng reduces Warfarin's effect in health patients. Ann Intern Med 2004, 141:23-27.
203. Kuo S.C., Teng C.M., Lee J.G., Ko F.N., Chen S.C., Wu T.S. Anti-platelet components in Panax ginseng. Planta Med 1990, 56:164-167.
204. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr 2007, 47(8):735-748.
205. Bano G., Amla V., Raina R.K., Zutsi U., Chopra C.L. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med 1987, 53:568-569.
206. Velpadian T., Jasuja R., Bhardwai R.K., Jaiswal J., Gupta S.K. Piperine in food: inference in pharmacokinetics to DPH. Eur J Drug Metab Pharmacokinet 2001, 26:241-247.
207. Pattanaik S., Hota D., Prabhakar S., Kharbanda P., Pandhi P. Effect of Piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res 2006, 20:683-686.
208. Zutshi U., Singh R., Zutshi R.K., Johri R.K., Atal C.K. Influence of piperine on rifampicin blood levels in patients with pulmonary tubercolosis. J Assoc Physicians India 1984, 33:223-224.
209. Bano G., Raina R.K., Zutshi U., Bedi K.L., Johri R.K., Sharma S.C. Effect of piperine on biovailability and pharmacokinetics of propanolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991, 41:615-618.
210. Gupta S.K., Bansal P., Bhardwaj R.K., Velpadian T. Comparative anti-nociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination. Pharmacol Res 2000, 41:657-662.
211. Hiwale A.R., Dhulev J.N., Naik S.R. Effect of co-administration of piperine on pharmacokinetics of beta-lactam antibiotics in rats. Indian J Exp Biol 2002, 40(3):277-281.
212. Mujumdar A.M., Dhulev J.N., Deshmukh V.K., Raman P.H., Naik S.R. Anti-inflammatory activity of piperine. Jpn J Med Sci Biol 1990, 43(3):95-100.
213. Bioperine.com [internet]. Sabinsa Corporation [updated 19 November 2009; cited 20 November 2009]. Available from: http://www.bioperine.com/.
214. Wilt T.J., Ishani A., Stark G., Macdonald R., Lau J., Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia - a systematic review. JAMA 1998, 280:1604-1609.
215. Fong Y.K., Milani S., Djavan B. Role of phytotherapy in men with lower urinary tract symptoms. Curr Opin Urol 2005, 15:45-48.
216. Yale S.H., Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005, 11(3):433-439.
217. Markowitz J.S., Donovan J.L., DeVane C.L., Taylor R.M., Ruan Y., Wang J.S., et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003, 74(6):536-542.
218. Greenle H., Abascal K., Yarnell E., Ladas E. Clinical applications of Silybum marianum in oncology. Integr Cancer Ther 2007, 6:158-165.
219. Post-White J., Ladas E.J., Kelly K.M. Advances in the use of milk thistle (Sylibum marianum). Integr Cancer Ther 2007, 6(2):104-109.
220. Comelli M.C., Mengs U., Schneider C., Prosdocimi M. Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther 2007, 6:120-129.
221. Hanje A.J., Fortune B., Song M., Hill D., McClain C. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr Clin Pract 2006, 21:255-272.
222. Zhang S., Morris M.E. Effect of the flavonoid Biochanin A and Silymarin on the P-Glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 2003, 20(8):1184-1191.
223. Piscitelli S.C., Formentini E., Burstein A.H., Alfaro R., Jagannatha S., Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002, 22(5):551-556.
224. DiCenzo R., Shelton M., Jordan K., Koval C., Forrest A., Reichman R., et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003, 23(7):866-870.
225. Mills E., Wilson K., Clarke M., Foster B., Walker S., Rachlis B., et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 2005, 61:1-7.
226. Rao B.N., Srinivas M., Kumar Y.S., Rao Y.M. Effect of silymarin on the oral biovaibility of ranitidine in healthy human volunteers. Drug Metabol Drug Interact 2007, 22:175-185.
227. Gurley B.J., Barone G.W., Williams D.K., Carrier J., Breen P., Yates C.R., et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2006, 34:69-74.
228. Gurley B.J., Hubbard M.A., Williams D.K., Thaden J., Tong Y., Gentry B., et al. Assessing the clinical significance of botanical supplementation on human cytochrome p450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 2006, 46:201-213.
229. Fuhr U., Beckmann-knopp S., Jetter A., Lück H., Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med 2007, 73(14):1429-1435.
230. Rajnarayana K., Reddy M.S., Vidysagar J., Krishna D.R. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 2004, 54:109-113.
231. A receptors: molecular mechanism and subunit specificity. Neuropharmacology 2007, 53:178-187.
232. Fernández S.P., Wasowski C., Paladini A.C., Marder M. Synergistic interaction between hesperidin, a natural flavonoid, and diazepam. Eur J Pharmacol 2005, 512:189-198.
233. Donovan J.L., DeVane C.L., Chavin K.D., Wang J.S., Gibson B.B., Gefroh H.A., et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004, 32(12):1333-1336.
234. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Khan I.A., et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1 and 3A4/5 phenotypes. Clin Pharmacol Ther 2007, 77(5):415-426.
235. Borrelli F., Capasso R., Pinto A., Izzo A.A. Inhibitory effect of ginger (Zingiber officinale) on rat ileal motility in vitro. Life Sci 2004, 74:2889-2896.
236. Baldreldin H.A., Blunden G., Tanira M.O., Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol 2008, 46:409-420.
237. Ghayur M.N., Gilani A.H. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci 2005, 50(10):1889-1897.
238. Bateman D.N. The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. Eur J Clin Pharmacol 1986, 30:205-208.
239. Greiff J.M., Rowbotham D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet 1994, 27(6):447-461.
240. Wu K.-L., Rayner C.K., Chuah S.-K., Changchien C.-S., Lu S.-N., Chiu Y.-C., et al. Effect of ginger on gastric emptying and motility in healthy humans. Eur J Gastroenterol Hepatol 2008, 20:436-440.
241. Jiang X., Blair E.Y., McLachlan A.J. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 2005, 46:1370-1378.
242. Chiesara E., Borghini R., Marabini L. Dietary fibre and drug interactions. Eur J Clin Nutr 1995, 49(Suppl 3):S123-S128.
243. Richter W.O., Jacob B.G., Schwandt P. Interaction between fibre and lovastatin. Lancet 1991, 338:706.
244. Brown D.D., Juhl R.P. Decreased biovailability of digoxin due to antiacids and kaolin-pectin. N Engl J Med 1976, 295:1034-1037.
245. Brown D.D., Juhl R.P., Warner S.L. Decreased biovailability of digoxin due to hypocholesterolemic interventions. Circulation 1978, 58:164-172.
246. Huupponen R., Seppala P., Iisalo E. Effect of guar gum, a fibre preparation, on digoxin and penicillin absorption in man. Eur J Clin Pharmacol 1984, 26:279-281.
247. Gin H., Orgerie M.B., Aubertin J. The influence of guar gum on absorption of metformin from the gut in healthy volunteers. Horm Metab Res 1989, 21:81-83.
248. Neugebauer G., Akpan W., Abshagen U. Interaktion von guar mit glibencalmide und bezafibrat. Beitr Infusionther Klin Ernah 1983, 12:40-47. German.
249. Dalli E., Milara J., Cortijo J., Morcillo E.J., Cosín-Sales J., Sotillo J.F. Hawthorn extract inhibits human isolated neutrophil functions. Pharmacol Res 2008, 57:445-450.
250. Cabrelle A., Dell'Aica I., Melchiori L., Carraio S., Brunetta E., Niero R., et al. Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease. J Leukoc Biol 2008, 83:212-219.
251. Nobili S., Lippi D., Witort E., Donnini M., Bausi L., Mini E., et al. Natural compounds for cancer treatment and prevention. Pharmacol Res 2009, 59:365-378.
252. Sartor L., Pezzato E., Garbisa S. (-)Epigallocatechin-3-gallate inhibits leukocyte elastase: potential of the phyto-factor in hindering inflammation, emphysema, and invasion. J Leukoc Biol 2002, 71:73-79.
253. Micale V., Mazzola C., Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol Res 2007, 56:382-392.
254. Araldi E.M., Dell'Aica I., Sogno I., Lorusso G., Garbisa S., Albini A. Natural and synthetic agent targeting inflammation and angiogenesis for chemoprevention of prostate cancer. Curr Cancer Drug Target 2008, 8(2):146-155.
255. Borrelli F., Ernst E. Black cohosh (Cimifuga racemosa) for menopausal symptoms: a systematic review of its efficacy. Pharmacol Res 2008, 58:8-14.
256. Tognolini M., Ballabeni V., Bertoni S., Bruni R., Impicciatore M., Barocelli E. Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis. Pharmacol Res 2007, 56:254-260.
257. Núñez-Sellés A.J., Delgado-Hernández R., Garrido-Garrido G., García-Rivera D., Guevara-García M., Pardo-Andreu G.L. The paradox of natural products as pharmaceuticals experimental evidences of a mango stem bark extract. Pharmacol Res 2007, 55:351-358.
258. Cabrelle A., Dell'Aica I., Melchiori L., Carraro S., Brunetta E., Niero R., et al. Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease. J Leukoc Biol 2008, 83(1):212-219.
259. Calapai G., Caputi A.P. Herbal medicines: can we do without pharmacologist?. Evid Based Complement Alternat Med 2007, 4:41-43.
260. EMEA Commitee for Medicinal Products for Human use (CHMP), Committee for Medicinal Products for Veterinary use (CVMP). Guideline on specification test procedures and acceptance criteria for herbal substance, herbal preparations and herbal medicinal products/traditional herbal medicinal products. 2000 Doc. Ref. CPMP/QWP/2820/20 Rev1-EMEA/CVMP/815/00 Rev1 [cited 2008 Dec 1]. Avaible from: http://www.emea.eu.int/pdfs/human/qwp/282000en.pdf.
261. Herrlinger C., Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001, 15(6):897-918.
262. Bruno J.J., Ellis J.J. Herbal use among US elderly: 202 national health interview survey. Ann Pharmacother 2005, 39:643-648.
263. Mallal S., Nolan D., Witt C., Masei G., Martin A.M., Moore C., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
264. Mallal S., Phillips E., Carosi G., Molina J.-M., Workman C., Tomažič J., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
265. Tomlinson B., Hu M., Lee V.W.Y. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach?. Mol Nutr Food Res 2008, 52:799-809.
266. Fan L., Zhang W., Guo D., Tan Z.-R., Xu P., Li Q., et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 2007, 83(3):471-476.
267. Böttinger Y., Laine K., Andersson M.L., Korhonen T., Molin B., Ovesjö M.-L., et al. SFINX - a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 2009, 65(6):627-633.
268. Maliet L., Spinewine A., Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007, 370:185-191.
269. De Smet P.A.G.M., Floor-Schreudering A., Bouvy M.L., Wensing M. Clinical risk management of interaction between natural products and drugs. Curr Drug Metab 2008, 9:1055-1062.
270. U.S. Department of Health and Human Services, Office of Inspector General. Dietary supplement labels: an assessment 2003 [cited 2008 Dec 1]. Avaible from: http://www.oig.hhs.gov/oei/reports/oei-01-01-00121.pdf.
271. Figueiras A., Herdeiro M.T., Polónia T., Gestal-Otero J.J. An educational intervention to improve physician reporting of adverse drug reaction: a cluster-randomized controlled trial. JAMA 2006, 296(9):1086-1093.
272. Lin H.-W., Pickard A.S., Mahady G.B., Popovich N.G. Conceptual development of a measure to assess pharmacists' knowledge of herbal and dietary supplements. Am J Pharm Educ 2008, 72(3):1-8.
273. Sportiello L., Cammarota S., de Portu S., Sautebin L. Notification of undesirable effects of cosmetics and toiletries. Pharmacol Res 2009, 59:101-106.